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Background: Immunological changes in pregnancy are associated with improvements in some pre-existing
immune-mediated skin diseases. Estrogen has been hypothesized to contribute to these changes by creating a
shift fromTh1 and Th17 to Th2 immunity. As this hypothesiswould predict, psoriasis (a primarily Th17mediated
immune disease) tends to improve during pregnancy. However, the precise mechanism by which estrogen in-
duces immunological change in psoriasis remains poorly understood.
Objective: To summarize the immunologic effects of estrogen as they relate to psoriasis during pregnancy.
Methods:Weperformed anEnglish-language PubMed search of articles fromSeptember 2004 to September 2014
combining the key terms "psoriasis," "estrogen," "autoimmune disease," and "pregnancy."
Results: Estrogen appears to up-regulate Th2 cytokines and down-regulate Th1 and Th17 cytokines. This shiftwas
initially observed in murine systems, which showed decreased mixed lymphocyte reactions of splenocytes and
increased antibody production during pregnancy. Antigen stimulated splenocytes produced fewer Th1 cytokines
and more Th2 cytokines in pregnant mice. IL17 producing T cells were signiﬁcantly decreased in healthy preg-
nancies compared to non-pregnant controls.
Limitations: This review is limited by the paucity of studies evaluating immunological changes of psoriasis in
pregnancy among human subjects.
Conclusions: Increased estrogen production in pregnancy is associated with decreased Th1 and Th17 cytokine
production. While estrogen may be responsible for some of these immune shifts resulting in disease improve-
ment, there remains no deﬁnitive evidence to prove the hypothesis that estrogen is responsible for
such improvement.
© 2015 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
In pregnancy, there are a number of hormonal and immunological
changes that alter the severity of pre-existing cutaneous diseases and
cause new-onset cutaneous disease. Speciﬁcally, pregnancy triggers an
immune shift from T-helper 1 (Th1) to T-helper 2 (Th2) immunity,
which promotes fetal survival by decreasing the Th1 responses involved
in rejection of the fetus as an allograft. Pregnancy also leads to a de-
crease in T-helper 17 (Th17) frequency (Fu et al., 2013; Nakashima
et al., 2010a). As predicted, pregnancy is associated with an improve-
ment in numerous Th1 and Th17 immune-mediated diseases, including
psoriasis, rheumatoid arthritis, autoimmune encephalomyelitis, uveitis,
thyroiditis, and multiple sclerosis (Abramsky, 1994; Amino et al., 1999;se, M.D., Department of Derma-
amino Real (31-104), Mountain
4-7696.
on behalf ofWomen's Dermatologic SBirk et al., 1988; Chiam et al., 2013; Confavreux et al., 1998; Da Silva and
Spector, 1992; Damek and Shuster, 1997; Davies, 1999; Muller et al.,
1999; Ostensen, 1999; Rabiah and Vitale, 2003; Runmarker and
Andersen, 1995; Terry and Hague, 1998; van Walderveen et al., 1994;
Whitacre et al., 1999).
Psoriasis is an immune-mediated disease that is driven by Interleu-
kin 23 (IL23) and Th17 cells (Lowes et al., 2014), while Th1 cells may
play a secondary role (Austin et al., 1999; Schlaak et al., 1994; Szabo
et al., 1998; Uyemura et al., 1993). Older therapies for psoriasis have
aimed to down-regulate Th1 responses. Several systemic therapies are
beneﬁcial in treating psoriasis: methotrexate, cyclosporine, acitretin,
PUVA (oral psoralen and ultraviolet A light treatments), narrowband ul-
traviolet B (nUVB) light treatments, and hydroxyurea. An improved un-
derstanding of the immunologic mechanisms driving psoriasis has
allowed for the development of various biologic therapies (Table 1) in-
cluding etanercept, adalimumab, inﬂiximab, and ustekinumab. A num-
ber of IL23 and IL17 antagonist are currently being tested in clinical
trials. Each of these therapies has at least in part an anti-inﬂammatory
mechanism of action related to immune deviation (Kang et al., 1998;
Krueger, 2002).ociety. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
















Fig. 1.Methods used for literature search.
105M. Danesh, J.E. Murase / International Journal of Women's Dermatology 1 (2015) 104–107The purpose of this article is to review the immunologic effects of es-
trogen on psoriasis during pregnancy. In understanding the role of es-
trogen on the immune system in pregnancy, we may be better able to
devise cost-effectivemedications like hormoneswith an improved safe-
ty proﬁle over that of systemic immunosuppression to provide thera-
peutic alternatives for psoriasis patients.
Methods
We performed an English-language PubMed search of articles in
September 2014 for articles dated from September 2004 to September
2014 combining key terms including "psoriasis," "estrogen," "autoim-
mune disease," and "pregnancy." All titles and/or abstracts were
screened. Full texts were obtained and content was further examined
for inclusion in this narrative review.
Results
Our electronic search yielded 404 articles, which were scanned by
the authors to retrieve relevant information on the immunologic effects
of estrogen on psoriasis. (Fig. 1)
Psoriasis in Pregnancy
Data suggest that psoriasis tends to improve with high estrogen
states. Retrospective studies examining psoriatic change in pregnancy
have shown that approximately half of patients improve during preg-
nancy, and up to 70% experience a postpartum ﬂare (Boyd et al., 1996;
Dunna and Finlay, 1989; Farber and Nall, 1974; Farber et al., 1968;
McHugh and Laurent, 1989; McNeill, 1988; Mowad et al., 1998; Park
and Youn, 1998). Murase et al performed the ﬁrst study that examined
body surface area (BSA) in pregnancy and the postpartum period, com-
paring 47 pregnant psoriasis patients with 27 non-pregnant psoriasis
patients (Murase et al., 2005). During pregnancy, 55% of patients report-
ed improvement, 21% reported no change, and 23% reportedworsening.
However, among postpartum patients, only 9% reported improvement,
26% reported no change, and 65% reported worsening. Psoriatic BSA de-
creased signiﬁcantly from 10 to 20 weeks' gestation (P b 0.001) com-
pared with controls, whereas BSA increased signiﬁcantly by 6 weeks
postpartum (P = 0.001) compared with controls. In patients with 10%
or greater psoriatic BSA who reported improvement, lesions decreased
by 83.8% during pregnancy. There were signiﬁcant or near signiﬁcant
correlations between improvement in BSA and estradiol levels (P =
.009, r = 0.648), estriol (P = .06, r = 0.491), and the ratio of estrogen
to progesterone (P = .006, r = 0.671).
Patients treated with high dose estrogen oral contraceptives experi-
ence improvement of their psoriasis (Mowad et al., 1998) and psoriatic
arthritis (McHugh and Laurent, 1989). In contrast, psoriasis worsens
when estrogen levels drop postpartum (Boyd et al., 1996; Dunna and
Finlay, 1989; McNeill, 1988; Mowad et al., 1998), prior to menses
(Mowad et al., 1998), and at menopause (Mowad et al., 1998).
Exogenous estrogen treatment in a prospective clinical trial has
never been done in psoriasis.Table 1
Selected biologics tested in psoriasis
Drug Target
Ustekinumab (Stelara) IL-12 and IL-23 shared
Briakinumab IL-12 and IL-23 shared
LY2525623 SCH 900222, CNTO 1959, AMG 139 Anti-IL-23 p19 subunit
Etanercept TNFα Receptor fusion p
Inﬂiximab, adalimumab Anti-TNF monoclonal a
Secukinumab, IL-17
Ixekizumab, brodalumab IL-17
Created with information from Lowes et al. (2014)The Immunology of Psoriasis
Initially, evidence supporting the immunopathogenicity of Th1 cells
in psoriatic lesions came from data demonstrating that Interferon-γ
(IFNγ), Tumor Necrosis Factor-α (TNFα) and IL12 were detected by
RT-PCR in lesions, while levels of IL4, IL5 and IL10were low to undetect-
able This pattern of cytokine expression was also observed using ﬂow
cytometry of cells derived from lesions (Austin et al., 1999; Schlaak
et al., 1994; Szabo et al., 1998; Uyemura et al., 1993). TNFα immunore-
activity and bioactivity were consistently higher in lesions, as compared
with uninvolved (clinically normal) skin samples (Ettehadi et al., 1994).
However, more recent evidence indicates that psoriasis is driven by
IL17 producing T cells (Th17 cells), rather than Th1 cells. In 2004, Lee
et al showed that lesional skin had an increase in IL23 (Lee et al.,
2004), a cytokine secreted by dermal dendritic cells and monocytes
(Fuentes-Duculan et al., 2010). Furthermore, studies have documented
an abundance of IL17 producing cells in psoriasis (Kryczek et al., 2008;
Lowes et al., 2008; Ortega et al., 2009). These two cytokines, IL17 and
IL23, are closely linked: IL23 is required for the expansion of Th17
cells (Lowes et al., 2014) Overall, it appears that Th1 and Th17 cells col-
laborate to contribute to the immuno-pathogenicity of psoriasis
(Kryczek et al., 2008; Ortega et al., 2009).
Many treatments for psoriasis act at least in part through therapeutic
immune deviation (Kang et al., 1998; Krueger, 2002). Particular empha-
sis has been placed on the pathogenic role of TNFα and the protective
role of IL10. Three of the currently used biologics for psoriasis
(Inﬂiximab, Adalimumab, and Etanercept) are anti-TNFα therapies.
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risk of developing neutralizing antibodies (Asadullah et al., 1998,
1999, 2000, 2001; Friedrich et al., 2002). Ustekinumab, a highly effective
biologic medication, induces its effects via antagonism of IL23, which in
turn, inhibits Th17 cell proliferation. Severalmedications that block IL17
(Secukinumab, Ixekizumab, Brodalumab) show great promise thus far
in Phase 2 clinical trials (Brown et al., 2015). Thus, previous studies
provide evidence that a systemic treatment with the ability to decrease
IL23, IL17, TNFα and/or increase IL10 would be beneﬁcial in
psoriasis patients.
The Immunology of Pregnancy
In both mice and man, failure to shift from Th1 to Th2mediated im-
munity in pregnancy results in an increase in spontaneous abortion (Hill
et al., 1995; Krishnan et al., 1996a; Lin et al., 1993). This shift in immune
response from Th1 to Th2 occurs both locally at thematernal fetal inter-
face (Lin et al., 1993; Sacks et al., 2001;Wegmann et al., 1993) aswell as
systemically (Dudley et al., 1993; Elenkov et al., 2001; Fabris et al., 1977;
Hill et al., 1995; Krishnan et al., 1996b; Marzi et al., 1996). The systemic
shift away from Th1 and toward Th2was initially shown in murine sys-
tems by a decrease in mixed lymphocyte reactions of splenocytes and
an increase in antibody production during pregnancy (Fabris et al.,
1977). Antigen stimulated splenocytes produce fewer Th1 cytokines
and more Th2 cytokines when derived from pregnant mice (Dudley
et al., 1993; Krishnan et al., 1996a). In humans, peripheral blood mono-
nuclear cells (PBMC) in women with successful pregnancies produced
IL-10, but no IFNγ, upon stimulation with trophoblast antigens (Hill
et al., 1995). In another study, antigen- and mitogen-stimulated PBMC
derived from patients with normal pregnancies demonstrated a de-
crease in the production of IL-2 and IFNγ and an increase in production
of IL-4 and IL-10, with the lowest quantities of IL-2 and IFNγ and the
highest quantities of IL-4 and IL-10 present in the third trimester of
pregnancy (Marzi et al., 1996). During the third trimester of pregnancy,
ex vivo monocytic IL-12 production was also found to be about three-
fold and TNFα production was approximately 40% lower than postpar-
tum values (Elenkov et al., 2001).
The Th1/Th2 paradigm has recently been expanded to include a
third population of T cells: Th17 cells. Santner-Nanan showed that the
percentage of Th17 cells is signiﬁcantly decreased in healthy pregnan-
cies compared to non-pregnant controls (Santner-Nanan et al., 2009).
However, the number of circulating Th17 cells does not change during
normal pregnancy (Nakashima et al., 2010a). In patients with unex-
plained recurrent spontaneous abortions (URSA), the proportion of
Th17 cells was signiﬁcantly higher in the peripheral blood and decidua
compared to the proportion in early, normal pregnant women (Wang
et al., 2010). Speciﬁcally, Th17 cells may play a role in the induction of
inﬂammation in the late stage of abortion (Nakashima et al., 2010b).
Conversely, the frequency of T-regulatory (Treg) cells was signiﬁcantly
lower in the patients with URSA (Wang et al., 2010). Also, amniotic
IL17 levels are elevated in patients with chorioamnionitis associated
with pre-term labor, and plasma IL17 levels are elevated in patients
with unexplained infertility (Ito et al., 2010). Altogether, these studies
indicate that normal pregnancy induces a shift away from Th17 immu-
nity, and that increased plasma IL17 levels have a negative impact
on fertility.
A signiﬁcant decrease in the Th1 response, the delayed type hyper-
sensitivity (DTH) response to the recall antigen tetanus, has been docu-
mentedduringpregnancy andduring treatmentwith estradiol (Holland
et al., 1984; Jansson et al., 1990; Manyonda et al., 1992). This was sup-
ported by changes in PBMC cytokine production when an estrogen
was administered in vitro to treat human T cell lines (Correale et al.,
1998; Gilmore et al., 1997; Zang et al., 2002). Estrogen also appears to
suppress murine IL17 production, as seen in Th17 mediated diseases
such as autoimmune encephalomyelitis and collagen-induced arthritis
(Bebo et al., 2001; Jansson et al., 1994; Tyagi et al., 2012). Finally,there have been previous reports that the state of pregnancy can alter
subpopulations of circulating immune cells, but there is no clear consen-
sus regarding consistent changes at each trimester in humans
(Mahmoud et al., 2001; Makrydimas et al., 1994; Matthiesen et al.,
1996; Tallon et al., 1984; Watanabe et al., 1997).
Discussion
Pregnancy is associated with diminished Th1 and Th17 immunity.
Both T-helper cells are postulated to play a role in the pathogenesis of
psoriasis, and the dampening of their respective cytokines by targeted
biologic therapy leads to disease improvement. Associations provided
by the literature suggest that the high estrogen state of pregnancy is
perhaps one factor for these immune shifts, and thus disease improve-
ment. However, there is no deﬁnitive evidence to demonstrate the hy-
pothesis that estrogen improves psoriasis in pregnancy. Without
further studies showing that the absence of estrogen (e.g. an estrogen
knockout or anti-estrogen antibody) could block such improvement,
this hypothesis remains speculative.
Our review is not without limitations. First, our report is limited by
the paucity of studies evaluating immunological changes of psoriasis
in pregnancy among human subjects. As a substitute, we have usedmu-
rine models to understand some of the immunologic effects during
pregnancy. However, there is a much clearer dichotomy between mu-
rine immune responses as either Th1 or Th2 than in humans (Kidd,
2003). As a result, the role of estrogen on the murine immune system
may not lend itself as well to extrapolation in the pregnant woman.
Also (related to ourﬁrst limitation), we included non-randomized stud-
ies in this review, which may introduce some selection bias. However,
because we are studying psoriasis in pregnant women, most of the
data in humans is from non-randomized studies rather than random-
ized studies (due to ethical considerations).
There remains great need for further research to advance our under-
standing about the effects of estrogen on psoriasis. We recommend fur-
thermurine studies that evaluate the speciﬁc role of estrogen in disease
improvement. Perhaps in the future, studies may be performed using
estrogen as the primary treatment modality for patients who have pso-
riasis. Speciﬁcally we recommend studying the experimental use of es-
triol, which is an estrogen unique to pregnancy that is associated with
fewer adverse effects than estradiol (Follingstad, 1978; Lauritzen,
1987). We believe this research would be an essential ﬁrst step in ad-
vancing our understanding of the immunologic effects of estrogen on
psoriasis and, even more importantly, the development of an inexpen-
sive topical or oral treatment for psoriasis which could potentially
have an improved safety proﬁle over systemic immunosuppresants for
women of childbearing age.
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